True Light Investments P Pte. Ltd., Daxue Investments Pte. Ltd., HLC VGC Fund IV L.P. and Qingdao Hongyi Investment Partnership Enterprise (Limited Partnership) entered into an agreement to acquire an unknown minority stake in Viva Biotech (Shanghai) Ltd. from Viva Biotech Holdings (SEHK:1873) for CNY 514.6 million on June 10, 2023. The shareholders? meeting and the board of directors of VIVA Shanghai have approved (i) the entering into of the Transaction Documents and the completion of the proposed transactions under the Transaction Documents. For the year ended December 2022, Net Assets were of CNY 1.15 billion, Profit after tax was of CNY 202 million. The Company intends to apply such proceeds to redeem the December 2025 Convertible Bonds.

True Light Investments P Pte. Ltd., Daxue Investments Pte. Ltd., HLC VGC Fund IV L.P. and Qingdao Hongyi Investment Partnership Enterprise (Limited Partnership) completed the acquisition of an unknown minority stake in Viva Biotech (Shanghai) Ltd. from Viva Biotech Holdings (SEHK:1873) on November 20, 2023.